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osting by EAbstract Resveratrol, the red-wine polyphenol, is intensively studied polyphenols for its pleiotro-
pic biological effects. A plethora of health beneﬁcial effects of this stilbene has been reported includ-
ing cardio-protective, neuro-protective, anti-cancer, anti-diabetic and interesting anti-aging.
Though it has been proposed that these effects of resveratrol arise from its capacity to interact with
multiple molecular targets involved in diverse intracellular pathways including activation of sirtu-
ins, the antioxidant property of this compound is the most described one to attribute its diverse
health beneﬁcial effects. In the present review we have explained the biological activities of resve-
ratrol with the latest laboratory evidences towards its antioxidant effects.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Herbal medicines have been used for thousand years to ﬁght
diseases and improve body functions. Polyphenols present in
these herbal remedies are considered as major nutrients
responsible for improving general health and for providing
cure for certain speciﬁc pathological conditions (Pandey and
Rizvi, 2009a). Resveratrol is a naturally occurring polypheno-015305910.
Rizvi).
y. Production and hosting by
Saud University.
lsevierlic compound found largely in the skins of the grapes (Vitis
vinifera) and the products prepared from it such as red-wine,
however presence of resveratrol has been identiﬁed in several
other plant species except grapes such as peanuts, berries
and legumes (Aggarwal et al., 2004). Its stilbene-based struc-
ture has two phenolic rings linked by a styrene double bond,
which allows cis and trans orientation to generate 3,40,5-tri-
hydroxystilbene (Fig. 1) (Markus and Morris, 2008).
Resveratrol has a long history of serving mankind as part
of several herbal medicinal preparations all over the world.
Roots of Polygonum cuspidatum, a plant used in traditional
Chinese and Japanese folk medicine has been found to be rich
in resveratrol. The primary impetus for research on resveratrol
came from the paradoxical observation of a low incidence of
cardio-vascular diseases that coexist with intake of a high-fat
diet and moderate consumption of red-wine in certain popula-
tions, a phenomenon known as French paradox (Renaud and
de Lorgeril, 1992; Siemann and Creasy, 1992).
Several studies within the last few years have demonstrated
that resveratrol may prevent or slow the progression of a wide
variety of human diseases, including cancer, cardio-vascular
Figure 1 Chemical structure of resveratrol.
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stress resistance and extend the life-spans of a variety of organ-
isms from yeast to vertebrates (Fig. 2) (Jang et al., 1997; Mark-
us and Morris, 2008; Pandey and Rizvi, 2009b). Activation of
sirtuins, a class of nicotinamide adenine dinucleotide (NAD+)-
dependent deacetylases, modulation of cell cycle regulatory
genes, activation of transcription factors and inhibition of pro-
tein kinases are some proposed mechanisms of action of resve-
ratrol (Marques et al., 2009), however, the anti-oxidative
property is one of the most documented biological activity of
resveratrol for its diverse biological effects. The aim of the
present review is to highlight the latest ﬁndings that are
responsible for the increased recognition of resveratrol as a po-
tent antioxidant agent.
2. Reactive oxygen species and oxidative stress
Reactive oxygen species (ROS) is a collective term that in-
cludes oxygen-centered radicals and oxygen-centered non rad-
icals that are continuously produced as a byproduct during
normal metabolic processes inside the human body. Exoge-
nous factors such as UV exposure, herbicides, xenobiotics
and air pollutants also cause the generation of ROS. ROS elicit
negative effects on the biomolecules and alter/modulate the
normal function of the cell. ROS have been also known to in-
duce proliferation, senescence, necrosis, apoptosis or cell death
(Simon et al., 2000).
To overcome the deleterious effects of ROS, antioxidant
systems are inherently present in human body. However due
to over generation of ROS/weak defense systems, an imbal-Figure 2 Diverse health beneﬁcial effects of resveratrol. Anti-
cancer and cardio-protective effects are ﬁrst reported biological
effects of resveratrol. Prolongation of life span in lower vertebrates
and protective effects in many age related diseases are some
evidences to establish resveratrol as anti-aging agent. However
anti-diabetic, analgesic, anti-arthritis, anti-asthma and immunity
enhancement effects are some currently reported biological effects
of resveratrol.ance occurs between this redox system and the condition of
oxidative stress develops. Oxidative stress is always deleterious
and it causes damage to tissues in many ways (Sies, 1986;
Halliwell, 2007).
Oxidative stress changes the ion balance that triggers many
other deleterious events such as cellular volume changes
(Schliess and Ha¨ussinger, 2002). Oxidative stress causes dam-
age to a wide range of biomolecules including proteins, lipids
and nucleic acids, making them oxidized and malfunctioned.
In clinical studies oxidative stress has been associated with
many degenerative diseases such as atherosclerosis, cancer,
trauma, stroke, asthma, hyperoxia, arthritis, age pigments,
dermatitis, cataractogenesis, retinal damage, hepatitis and
aging (Halliwell and Gutteridge, 2006; Pandey and Rizvi,
2010b).
3. Resveratrol as a potent antioxidant
Resveratrol is reported to one of the most potent antioxidant
against ROS and oxidative stress. ROS production by poly-
morphonuclear leukocytes stimulated by formylmethionyl leu-
cyl phenyalanine (fMLP) can be strongly inhibited by
resveratrol (Rotondo et al., 1998). Mizutani and co-workers
(2001) showed that resveratrol signiﬁcantly reduces markers
of oxidative stress like glycated albumin in serum and 8-
hydroxyguanosine in urine in stroke-prone spontaneously
hypersensitive rats. Moreover, resveratrol could act on targets
in blood cells and in lipoproteins. Indeed, resveratrol was
incorporated into blood cells and lipoproteins after in vitro
incubation with plasma, lipoproteins, and cells (Blache et al.,
1997). In fact, due to its lipophilic character, resveratrol is able
to bind the lipoprotein particles suggesting that this event im-
proved its antioxidant activity (Belguendouz et al., 1998). Here
we will discuss the effect of resveratrol on some most reliable
and authentic parameters of oxidative stress to explain the ex-
tent of anti-oxidative effects of resveratrol.
3.1. Resveratrol and lipid peroxidation
Lipids are the important constituents of membranes and func-
tion as steroid hormones, retinoic acids and prostaglandins. In
view of increasing evidence showing the involvement of free
radicals in biology, lipid peroxidation has received renewed
attention from wider viewpoints in the ﬁelds of chemistry, bio-
chemistry, nutrition, and medicine. Studies have revealed that
lipid peroxidation severely affects biomembranes including dis-
turbance in ﬁne structures, alteration of integrity, ﬂuidity, per-
meability and functional loss and also modiﬁes low density
lipoprotein (LDL) to pro-atherogenic and pro-inﬂammatory
forms, and generates potentially toxic products (Greenberg
et al., 2008). Lipid peroxidation products have also been
shown to be mutagenic and carcinogenic (West and Marnett,
2006) and has been implicated as the underlying mechanisms
in numerous disorders and diseases such as cardio-vascular
diseases, cancer, neurological disorders, and also in aging
(Lee et al., 2004; Rizvi and Maurya, 2007).
A measurable increase in plasma antioxidant level and de-
creased lipid peroxidation has been seen after consumption
of resveratrol or resveratrol-rich diet (Wenzel et al., 2005).
An association has been found between oxidation of LDL par-
ticles and risk of heart diseases and myocardial infractions
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LDL by chelating copper and by scavenging ROS. The fact
that resveratrol can be detected in LDL particles after red-wine
consumption by humans is consistent with its ability to prevent
peroxidation of lipids and other macromolecules (Markus and
Morris, 2008).
The efﬁciency and action mechanism of trans-resveratrol
have been demonstrated in the radical liposome oxidation
where it appeared that the para-hydroxyl groups show a great-
er radical-scavenging activity than the meta-hydroxyl groups
of trans-resveratrol (Stojanovic et al., 2001). Moreover, the
spatial position of hydroxyl groups is likely more propitious
to the chelation of copper in the trans-isomer than in the cis-
isomer. It has been reported that due to hydroxylated structure
of resveratrol, it can form a radical derivative stabilized by the
delocalization of two electrons between the two aromatic cy-
cles and the methylene bridge joining these two cycles (Delmas
et al., 2005).
Resveratrol is also reported to reduce the intracellular ROS
and to prevent the LDL oxidation in endothelial cells (Delmas
et al., 2005). Oxidation induced by endothelial cells depends on
lipoperoxides generated intracellularly and then transferred to
the LDL. Cellular lipoxygenases (LO), especially 15-LO, ap-
pear to be involved. Various studies demonstrate that resvera-
trol inhibits lipoxygenases, in particular in human neutrophils
where resveratrol strongly inhibits the 5-LO and 15-LO pro-
ducing various pro-inﬂammatory products in the arachidonate
metabolism (MacCarrone et al., 1999). In addition resveratrol
was able to decrease the accumulation of hydroperoxides in
LDL promoted by ferromyoglobin by reduction of the oxofer-
ryl complex to metmyoglobin. Resveratrol also inhibited LDL
apoprotein modiﬁcations induced by peroxynitrite (Brito et al.,
2002).
In 2008, Dani and co-workers showed that resveratrol has
ability to prevent lipid peroxidation and intracellular oxidation
in Saccharomyces cerevisiae. They have reported that after res-
veratrol treatment, the levels of ROS produced in Saccharomy-
ces in response to peroxide were almost 3-fold lower,
suggesting that resveratrol has a high capacity to eliminate hy-
droxyl radicals formed by a Fenton reaction.
One of the most often used biomarker to investigate the
oxidative damage on lipids is malondialdehyde (MDA), a ma-
jor lipid peroxidation product. It can react with the free amino
group of proteins, phospholipids, and nucleic acids leading to
structural modiﬁcation, which can induce dysfunction of im-
mune systems. A high level of MDA can be detected in cell
degradation after cell injury or disease (Pandey et al.,
2009a,b). A very recent study done in our lab showed that
the presence of resveratrol in incubation media very effectively
protected the erythrocyte lipids from peroxidation as evi-
denced by the almost normal (control) values of the MDA in
cells even after induction of oxidative stress (Pandey and Rizvi,
2009c). In 2003, Leonard and co-workers have reported that
that resveratrol can scavenge ROS as measured by spin trap-
ping competitions using sodium formate as a second free rad-
ical scavenger, and is effective in inhibiting lipid peroxidation
of cellular membranes. Ray et al. (1999) have reported that
MDA formation in the coronary efﬂuents of the resveratrol-
treated hearts was signiﬁcantly lower than those of control ani-
mals, suggesting reduced free radical formation in the hearts
pretreated with resveratrol. Protective role of resveratrol in
MDA formation in naphthalene-induced oxidative stressedmice is also reported (Sehirli et al., 2008). Moreover, intraperi-
toneal resveratrol administration has been shown to reduce li-
pid peroxidation and tissue damage in ischemia/reperfusion
(Shigematsu et al., 2003) and cholestasis models (Ara et al.,
2005). In an in vitro study examining the antioxidant activities
of resveratrol and its analogues, the results exhibited that they
had various potencies in inhibiting lipid peroxidation in rat
brain, kidney and liver homogenates and rat erythrocyte
hemolysis (Lu et al., 2002).
Interestingly, the effect of resveratrol on protection of lipids
from peroxidation is quite fast, within half an hour it showed
the signiﬁcant protection (Pandey and Rizvi, 2009c). Time
dependent effect of resveratrol may be explained from the ﬁnd-
ings of Bertelli et al. (1996) and Goldberg et al. (2003), in
which they have documented that resveratrol was rapidly ab-
sorbed and its peak plasma concentration was achieved after
only 15–60 min of administration. Results from these studies
show that resveratrol has strong antioxidant property and also
has ability to provide protection against oxidation induced
damage to lipids under conditions that challenge the body’s re-
dox status.3.2. Resveratrol and oxidation of proteins
Resveratrol has also been reported for its strong role in pro-
tecting the proteins from being oxidized. Resveratrol protected
formation of membrane protein carbonyls (PCO) in red blood
cells and plasma under the condition of oxidative stress
(Pandey and Rizvi, 2009c, 2010a).
The attack by ROS against proteins modiﬁes amino acid
(lysine, arginine, proline, and histidine) residues generating
carbonyl moieties, which has been identiﬁed as an early marker
for protein oxidation and is used as a measure of protein dam-
age (Levine et al., 1990). Increase in protein carbonyls level is
direct evidence towards the fact that oxidative stress increases
as the antioxidant capacity of the body falls (Stadtman, 2001).
Oxidative damage has been reported to occur on all compo-
nents of biological systems however, proteins are likely to be
major targets of ROS due to their abundance in cells, plasma,
and most tissues, and their rapid rates of reaction both with
many radicals and with other oxidants. It has been reported
that proteins compose about 70% of the dry mass of most cells
(Hawkins et al., 2009). Since proteins often have unique bio-
logical functions, there are unique functional consequences
resulting from their modiﬁcation. Oxidation of proteins can
lead to a whole variety of amino acid modiﬁcations. Action
of chloraminated oxidants, mainly hypochlorous acid and
chloramines, produced by myeloperoxidase in activated neu-
trophils, forms dityrosine containing cross-linked protein
products known as advanced oxidation protein products
(AOPP) (Witko-Sarsat et al., 1996). Protein oxidation prod-
ucts mediated by chlorinated species generated by an enzyme
myeloperoxidase were found in the extracellular matrix of hu-
man atherosclerotic plaques and increased levels of AOPP
were described as an independent risk factor for coronary ar-
tery and renal diseases (Witko-Sarsat et al., 1996). Inhibition
of formation of AOPP and PCO by resveratrol directly advo-
cates its strong antioxidant effect (Pandey and Rizvi, 2010a).
Resveratrol has also been consistently shown to inhibit pro-
tein degradation and to attenuate atrophy of skeletal muscle
ﬁbers in vitro (Dirks Naylor, 2009). In 2007, Busquets et al.
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longus muscle in resveratrol signiﬁcantly reduced protein deg-
radation compared to control muscle. It appears that resvera-
trol may inhibit protein degradation by inhibiting the
activation and translocation of nuclear factor kappa beta
(NF-kB) to the nucleus (Dirks Naylor, 2009). Resveratrol
may inhibit activation of NF-kB via the inhibition of I-kB ki-
nase (IKK) (Holmes-McNary and Baldwin, 2000).
It has been reported that resveratrol supplementation
(1 mg/kg/day) in MAC 16 tumor bearing rats did signiﬁcantly
attenuate weight loss and protein degradation in skeletal mus-
cle as well as reduce the NF-kB activity (Wyke et al., 2004). In
2006, Ikizler et al., reported that resveratrol has excellent anti-
oxidant activity. It protected skeletal muscles from oxidative
stress and injury as determined by carbonyl and protein sul-
phydryl levels as well as venous levels of myoglobin, lactate
dehydrogenase, creatinine phosphokinase. Dirks Naylor,
2009 has been concluded that in skeletal muscle, resveratrol
has thus far been shown to alter metabolism, inhibit protein
catabolism, improve function, and protect against cellular
stress.Figure 3 Diagrammatic representation of relation between
oxidative stress parameters and effect of resveratrol (RESV)
treatment. In oxidative stress condition reduced/depletive level of
plasma antioxidant potential (PAP), reduced glutathione (GSH)
and total thiols (–SH) are reported. In contrast the level of
malondialdehyde (MDA), protein carbonyls (PCO) and advanced
oxidation protein products (AOPP) are elevated. Resveratrol
treatment reversed these conditions of oxidative stress.3.3. Resveratrol and endogenous antioxidant systems
To overcome deleterious effects of ROS, many antioxidant sys-
tems are inherently present in human body. In humans, the
antioxidant system includes a number of antioxidant enzymes
such as superoxide dismutase (SOD) and catalase (CAT), non-
enzymatic antioxidants such as reduced glutathione (GSH),
protein –SH and uric acid. It has been elaborated that resvera-
trol signiﬁcantly activates/ prevents the oxidation of these
endogenous antioxidant systems.
Resveratrol is able to induce cellular antioxidants and
phase 2 enzymes (Marques et al., 2009). These modiﬁcations
contribute to increase the resistance to cardiac cell injury elic-
ited by ROS. It has been found that resveratrol reduces the
generation of H2O2, and normalize levels of oxidized glutathi-
one reductase and myeloperoxidase activities (Jang and Pezz-
uto, 1999). By normalization of the ROS levels, resveratrol
limits the oxidative stress which inhibits NO synthesis by
eNOS necessary for vasorelaxation (Delmas et al., 2005).
GSH is a major intracellular non-protein sulphydryl com-
pound and is accepted as the most important intracellular
hydrophilic antioxidant (Melov, 2002). GSH has many biolog-
ical functions, including maintenance of membrane protein –
SH groups in the reduced form, the oxidation of which can
otherwise cause altered cellular structure and function. It plays
a key role in protecting cells against electrophiles and free rad-
icals. This is due to the nucleophilicity of the -SH group and to
the high reaction rate of thiols with free radicals (Manson,
1979). Stress resistance of many cells is associated with high
intracellular levels of GSH. A decreased GSH content may
predispose the cell to a lower defense against condition of oxi-
dative stress during several degenerative disease conditions
including aging and diabetes (Rizvi and Zaid, 2001; Rizvi
and Maurya, 2007).
In 2003, Yen et al. showed that resveratrol at concentra-
tions of 10–100 lM exerts great protection against H2O2 in-
duced oxidative injury through increased GSH levels.
Another study by Ates et al. (2007) conﬁrms that an elevation
in glutathione level is due to the free-radical scavenging prop-erties of resveratrol. In a time dependent study of capacity of
resveratrol to prevent oxidation of GSH in red blood cells, it
is found that resveratrol was very effective since only after
15 min of incubation (Pandey and Rizvi, 2010c).
In 2008, Sehirli et al. reported that naphthalene administra-
tion signiﬁcantly reduced the total antioxidant capacity of
plasma with a concomitant decrease in tissue antioxidant,
GSH levels. Furthermore, resveratrol treatment replenishes
the antioxidant status of plasma and the tissue and protected
against this toxicity (Fig. 3).
Resveratrol also showed very signiﬁcant protection of
erythrocyte membrane as well plasma total –SH groups from
the oxidizing effects of oxidative stress. In our study on the hu-
man blood resveratrol protected the depletion of total –SH
groups in concentration as well as time dependent manner
(Pandey and Rizvi, 2010c). The importance of –SH group to
overall cellular redox balance has been well emphasized. Mem-
brane oxidative damage has a great inﬂuence upon the mem-
brane mechanical properties. A reduced level of –SH content
has been reported in many human diseases including diabetes
and aging (Rizvi and Maurya, 2007; Pandey et al., 2009c).
Endogenous antioxidant enzymes are powerful means to
protect the body from adverse modiﬁcations of oxidative stress
and maintaining the redox balance. SOD catalyzes the dismu-
tation of superoxide radical to H2O2. Although H2O2 is not a
radical, it is rapidly converted by fenton reaction into OH rad-
ical which is very reactive. CAT metabolizes H2O2 into H2O, it
has been reported that oxidative stress is the primary factor
regulating the gene expression of these enzymes (Franco
et al., 1999). There are many experimental evidences that res-
veratrol induces the activity of these antioxidant enzymes. In
a study by Cao and Li (2004) investigating the mechanism
underlying the protective effects of resveratrol in various car-
diovascular disorders, it has been demonstrated that a number
of endogenous antioxidants and phase 2 enzymes, including
SOD, CAT, glutathione reductase (GR), glutathione S-trans-
ferase (GST), and NAD(P) H:quinone oxidoreductase 1
(NQO1) in cultured cardiomyocytes can be induced by low
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cally mediated up-regulation of cellular defenses is accompa-
nied by a markedly increased resistance to cardiac cell injury
elicited by ROS, and doxorubicin.
A study carried out by Upadhyay et al., in 2008, elaborates
that resveratrol shows a protective activity against hepatic tox-
icity as evidenced by its ability to modulate pyrogallol-induced
changes in hepatic toxicity markers, xenobiotic metabolizing
enzymes and oxidative stress. A recent study by Khan et al.,
2010, also provides evidence towards anti-oxidative enzyme
activating potential of resveratrol as evidenced by the up-reg-
ulation of activities of glutathione peroxidase (GPx), GR,
CAT and SOD by resveratrol in 6-hydroxydopamine-induced
oxidative damage and dopamine depletion in rat model of Par-
kinson’s disease.
4. Conclusion
In summary, present review provides enough evidence for the
potential of resveratrol to establish it as a strong antioxidant
which may provide effective protection against oxidative stress
implicated in the etiology and progression of several acute and
chronic diseases. However questions like bioavailability and
concentration to be used are still unanswered. The results from
clinical trials specially in humans are limited, further research
and more clinical studies are necessary in order to ensure efﬁ-
cacy of resveratrol as a dietary antioxidant to be used as
supplement.Acknowledgements
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